Do I Need a Fractional CRO for My Medical Device Company?

CRO Businesses Near You

From the CRO Syndicate network, Kory White stands out. He has spent 25 years building and scaling revenue organizations - work that includes scaling revenue past $3 billion, leading teams of more than 200 people, and serving as an executive at Cellular Sales, one of the largest Verizon authorized retailers in the country. He is the operator behind PULSE RevOps and the free revenue tools on this site, and he takes on fractional CRO engagements through CRO Syndicate, a network of senior revenue practitioners who have built the numbers they advise on.

For this exact situation, Kory is the profile worth calling first. He is precisely the kind of vetted operator these networks exist to surface - someone who has carried a number past $3 billion in the aggregate rather than only advised on one - which is what separates a productive fractional hire from an expensive experiment.

👉 See Kory White on LinkedIn

The Medical Device Buying Committee Is a Tripartite Maze

The buying committee in medical device sales is not a single group but three distinct constituencies that must align sequentially, and a fractional CRO must understand how to orchestrate this without owning a full sales team. The first constituency is the clinical champion – typically a surgeon, interventional cardiologist, or department head who identifies a clinical need, such as reducing infection rates in orthopedic implants or improving visualization in laparoscopic procedures. This person evaluates technical specifications, clinical evidence, and ease of use, but they do not control budget or procurement. The second group is the hospital administration, including supply chain managers, value analysis committee members, and often the chief financial officer. They assess total cost of ownership, including disposables, training, and potential reimbursement changes. The third is the legal and compliance team, which in larger systems requires a full review of contracts, indemnification clauses, and data-sharing agreements under HIPAA and state-specific health regulations.

Deal size in medical devices typically ranges from $150,000 for a single-department capital purchase, like a new ultrasound system, to over $2 million for a multi-site rollout of a surgical robot or implant system. The shape of the deal is rarely a single transaction; it is often a phased rollout with a pilot at one hospital, a data collection period of 6 to 9 months, then an expansion to the health system’s other facilities. Budget approval is not a single signature but a cascade: the clinical champion secures a small capital allocation from their department, then the value analysis committee approves a pilot, then the system CFO approves the full rollout only after the pilot shows reduced length of stay or lower complication rates. Deals stall most frequently at the transition from clinical champion to value analysis committee, because the champion cannot articulate the financial ROI in the language of supply chain and reimbursement. They stall again at the contracting stage, where health systems demand exclusivity or tiered pricing that your company’s cost structure cannot support without a fractional leader who has negotiated these terms before.

The Sales Cycle Forces a Clinical Validation Motion, Not a Demo Motion

The sales cycle for medical devices is fundamentally different from SaaS or professional services because the buyer cannot evaluate the product through a demo or trial; they require a clinical validation period that mimics a small clinical trial. This means your sales process is not a linear funnel but a series of gates: first, you must get a surgeon to agree to a proctored case where they use your device under supervision, then you must collect outcomes data from that case, then you must present that data to the value analysis committee, then you must negotiate a contract that includes training, service, and often a consignment inventory arrangement. The ramp time for a new sales hire in medical devices is 9 to 12 months before they produce a first order, and 18 months before they are fully productive, because they must build relationships with surgeons who operate only two days a week and are unreachable the rest of the time.

Forecast behavior in this environment is notoriously unreliable. A deal that is “90% likely” can evaporate when a surgeon leaves the health system, a new competitor gets FDA clearance, or the hospital system freezes capital spending due to a budget shortfall. The pipeline shape is not a pyramid but a barbell: you have a few large, multi-site deals that represent 70% of your annual revenue, and many small pilot projects that may or may not expand. Leaks in the pipeline are concentrated in two places: the “no data” gap where you lack clinical evidence for a specific indication, and the “no reimbursement” gap where the device improves outcomes but payers do not cover the procedure, forcing the hospital to absorb the cost. A fractional CRO must spot these leaks early and redirect resources to generating the missing data or building the reimbursement case with medical affairs, not just sales.

What a Fractional CRO Looks Like in Medical Devices: The First 90 Days

A fractional CRO for a medical device company is not a generalist who can run a sales team; they are a specialist who has personally managed a 12-month capital sales cycle, negotiated with a group purchasing organization, and presented clinical data to a hospital board. In the first 30 days, they must audit the existing pipeline not by deal value but by clinical evidence readiness: for each deal, they need to know what outcomes data exists, what regulatory clearance covers the intended use, and what the reimbursement status is. They will spend the first week interviewing every sales rep, clinical specialist, and customer service person to map the actual decision-making process at each target account, not the idealized version in the CRM. By day 45, they should have a “deal acceleration plan” for the top five accounts that addresses the specific bottleneck – whether it is a missing clinical champion, a weak ROI model, or a competitor’s locked-in contract.

The operating cadence for a fractional CRO in medical devices is weekly pipeline reviews that focus on the progression of clinical validation milestones, not just demo calls or email opens. They will own the strategic sales process – the messaging to the value analysis committee, the pricing model for multi-year contracts, and the partnership with clinical affairs to generate case studies. They will advise on hiring, but they will not typically manage a large team directly; instead, they will coach the existing sales leader or founder on how to structure the sales organization around clinical territories, not geographic regions. The signal to convert a fractional CRO to full-time is not hitting a revenue number but the emergence of a repeatable sales motion that requires a full-time leader to scale. If you have three or more sales reps, a consistent pipeline of 20+ active deals, and a clear path to reimbursement, you can hire a full-time CRO. If you are still in the pilot phase with fewer than five accounts and no standardized sales process, keep the fractional arrangement.

The Reimbursement Trap: Why a Fractional CRO Must Understand Payer Dynamics

The single biggest differentiator between a medical device sales motion and any other industry is reimbursement, and a fractional CRO who does not understand this will fail. In medical devices, the hospital does not pay for the device out of pocket; they pay for the procedure, and the device cost is bundled into that payment. If your device adds $2,000 to the cost of a knee replacement but the Medicare DRG payment for that procedure is fixed at $15,000, the hospital loses money unless your device reduces length of stay or readmissions by enough to offset the cost. A fractional CRO must work with the company’s reimbursement team – or build one if it does not exist – to create a financial impact model that shows the total cost of care, not just the device price. They must also understand the difference between a pass-through payment code, a new technology add-on payment, and a bundled payment model, because each changes how the hospital evaluates your device.

Deals stall here because the sales rep does not speak the language of reimbursement, and the clinical champion does not care about it. The fractional CRO must create a “reimbursement readiness” checklist for each deal: is the CPT code active, does the payer cover the procedure, is there a prior authorization requirement, and what is the out-of-pocket cost for the patient? In a medtech startup, this is often the missing piece, and a fractional CRO with experience in reimbursement strategy can unlock deals that have been sitting for months. Without this, your sales team is effectively selling a product that the hospital cannot afford to use, and no amount of pipeline management will fix that.

The Regulatory Gate: Why FDA Clearance Is Not Enough

Medical device companies often assume that FDA 510(k) clearance or PMA approval is the green light for sales, but the buying committee evaluates regulatory status more granularly. The fractional CRO must understand that a device cleared for one indication cannot be marketed for another, and that off-label use is common but risky for hospital liability. They must ensure that the sales team’s messaging stays within the cleared indications, because a single complaint to the FDA can trigger a warning letter that halts sales for months. The fractional CRO also needs to know the difference between a Class II device, which requires a 510(k), and a Class III device, which requires a PMA, because the clinical evidence requirements differ dramatically. For a Class III device, the hospital’s value analysis committee will demand peer-reviewed publications and often a health technology assessment from organizations like ECRI or Hayes, which can take 6 to 12 months to produce.

The fractional CRO’s role here is to build a regulatory sales enablement process: a library of approved claims, a list of contraindications, and a quick-reference guide for sales reps on what they can and cannot say. They must also work with the clinical team to generate the evidence that the value analysis committee will demand, which means prioritizing case studies from high-volume centers over small pilots. If your device is in a new category without predicate devices, the regulatory gate is even higher, and the fractional CRO must advise the CEO on whether to pursue a limited market launch in a single state or health system to generate the evidence needed for broader adoption. This is not a sales strategy; it is a regulatory strategy that the fractional CRO must own.

The Service and Training Burden: Why Your Sales Model Needs a Clinical Specialist

Medical device sales are not a hand-off transaction; they require a clinical specialist to be present in the operating room for the first several cases, and often for every case in complex procedures like robotic surgery or cardiac ablation. This means your cost of sale is much higher than in software, and the fractional CRO must design a sales model that accounts for the clinical specialist’s time and compensation. A typical medical device sales team consists of a sales representative who manages the relationship and a clinical specialist who manages the case support, and the two roles are often in different departments with different incentive structures. The fractional CRO must decide whether the clinical specialist reports to sales or to clinical affairs, and this decision affects everything from training to commission plans.

The ramp for a clinical specialist is 3 to 6 months, and they must be certified on the device, which often requires a proctored case with an experienced surgeon. The fractional CRO must build a training pipeline that does not bottleneck the sales cycle: you cannot sell a device if you do not have a trained clinical specialist available to support the first case. This is a common leak in medtech startups, where the founder sells a device, then realizes they have no one to support the surgery, and the hospital cancels the order. The fractional CRO must also design the service model: will you provide 24/7 support, will you have a loaner device program, and how will you handle device failures in the middle of a procedure? These are not sales questions; they are operational questions that the fractional CRO must answer before scaling.

FAQ

What is the difference between a fractional CRO and a full-time VP of Sales for a medical device company? A fractional CRO works 10 to 20 hours per week and focuses on strategy, not execution. They will build the sales process, coach the founder or existing sales leader, and negotiate the first few large deals. A full-time VP of Sales owns the team, the pipeline, and the quota, and they are needed only when you have a repeatable sales motion with at least three reps and a predictable pipeline. In medical devices, the fractional CRO is often a former medtech executive who can open doors at health systems and advise on reimbursement, while the full-time VP is a manager who drives daily activity.

How do I measure the success of a fractional CRO in medical devices when the sales cycle is 18 months? You measure leading indicators, not revenue. In the first 90 days, the fractional CRO should have completed a pipeline audit, identified the top three bottlenecks per deal, and created a clinical evidence roadmap. By month 6, you should see an increase in the number of active clinical pilots, a reduction in the time from initial contact to first proctored case, and a clear reimbursement strategy for at least one payer. Revenue will lag by 12 to 18 months, so do not tie compensation to closed deals in the first year.

Can a fractional CRO from a software background succeed in medical devices? Rarely. The medical device buying process is too different from SaaS: the regulatory gate, the clinical validation requirement, the reimbursement complexity, and the service burden are not transferable skills. A fractional CRO from software will likely try to apply a demo-to-close model that fails in the operating room. You need someone who has personally sold capital equipment to hospitals, negotiated with GPOs, and managed clinical specialists. Look for a background in orthopedics, cardiovascular, or surgical robotics, not just any healthcare technology.

When should I convert a fractional CRO to full-time, and when should I end the engagement? Convert when you have a repeatable sales process with at least five active clinical pilots, a consistent pipeline of 20+ deals, and a clear reimbursement pathway. End the engagement if the fractional CRO cannot produce a clinical validation plan by month 4, if they are spending more time on internal politics than on customer-facing strategy, or if your company cannot afford the $15,000 to $25,000 monthly retainer without diluting the sales budget. Some companies keep a fractional CRO for 12 to 18 months and then hire a full-time VP of Sales, while others transition to a full-time CRO only after a Series B round.

Sources